FEATURES OF THE COURSE OF CHRONIC DERMATOSES IN PATIENTS WHO RECEIVED IMMUNOSUPPRESSIVE THERAPY

The aim of the work was to evaluate the impact of immunosuppressive therapy with glucocorticoids and cytostatic drugs on the course and prognosis of chronic dermatoses. Materials and methods. 192 patients with severe chronic dermatoses (psoriasis – 169 people, pemphigus vulgaris – 23) were involved in the study. The examined cohort included 90 females (46.9%) and 102 males (53.1%), as well as a control group of 17 clinically healthy individuals. 67 patients with psoriasis (34.9%) previously received immunosuppressive therapy (21 (31.3%) – cytostatic immunosuppressants + systemic glucocorticosteroids, 16 (23.9%) – systemic glucocorticosteroids, 30 (44.8%) – cytostatic immunosuppressants). All patients with pemphigus vulgaris previously received immunosuppressive therapy, and 13 patients (56.5%) received systemic glucocorticosteroids, 10 (43.5%) received a combination of systemic glucocorticosteroids and cytostatic immunosuppressants. The results. The frequency of infectious bacterial complications in different groups of patients with psoriasis was distributed as follows: in 37.5% of patients treated with systemic glucocorticosteroids and 19.0% of patients with a combination of systemic glucocorticosteroids and cytostatic immunosuppressants, on the other hand, 3.9% did not prevail among patients who received immunosuppressive therapy. And in patients with pemphigus vulgaris, we noted manifestations of pyoderma in almost all patients – in 92.3% of patients receiving systemic glucocorticosteroids, and in 70% of patients receiving combined therapy of systemic glucocorticosteroids and cytostatic immunosuppressants. Conclusions. Available treatment methods lead to an increase in the torpid course, the development of complications as a result of treatment, and a shortening of the remission period. It is necessary to develop and improve methods of therapy and prevention of its complications.